Travere reports Q2 2026 results as FSGS launch begins and civorebrutinib deal closes

Travere Therapeutics reported second quarter 2026 results on August 4, 2026, highlighting early momentum in its newly launched FSGS indication alongside continued IgA nephropathy demand. The first months of the FSGS launch and continued growth in IgAN resulted in 2,012 new patient start forms received during the second quarter of 2026.¹

On the regulatory front, in April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome.¹ FILSPARI is the first and only FDA-approved medicine for FSGS, with an estimated addressable population in the U.S. of more than 30,000 patients without nephrotic syndrome.¹ In IgAN, the SPARX Study evaluating FILSPARI in post-transplant patients with recurrent IgAN or FSGS has completed enrollment, with data presentations anticipated in 2027.¹ Separately, in June 2026 the company's partner, Chugai Pharmaceutical, submitted a New Drug Application for sparsentan in Japan.¹

The company also plans further FSGS study work: in the second half of 2026, the company plans to initiate a Phase 4, open-label, single-arm, multi-center study to further evaluate FILSPARI in adult and pediatric patients of African ancestry with FSGS and at high risk of disease progression, called SPARLIGHT.¹

In the rare disease pipeline, the company is continuing to enroll new patients in the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria, with topline data anticipated in the second half of 2027; the study is expected to enroll approximately 70 patients aged 12 to 65 with plasma total homocysteine levels of 50 µM or higher, with the primary endpoint measuring change from baseline in plasma tHcy averaged across weeks 6 through 12.¹

Travere expanded its pipeline through licensing. In July 2026, the company closed an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an investigational oral, covalent reversible Bruton's tyrosine kinase inhibitor, obtaining rights in the U.S. and global markets excluding Greater China and certain East and Southeast Asian countries.¹ Travere plans to investigate civorebrutinib in primary membranous nephropathy, immune-mediated FSGS and minimal change disease, with potential for additional indications.¹

On cash, as of June 30, 2026, the company had cash, cash equivalents, and marketable securities of $489.2 million.¹ In July 2026, the company made a $112.5 million upfront cash payment to Everest Medicines following the closing of the civorebrutinib in-licensing transaction.¹